Roche Holding AG Ordinary Shares new
ROP: XSWX (CHE)
| Morningstar Rating for Stocks | Fair Value | Economic Moat | Capital Allocation |
|---|---|---|---|
| B!# | LOCK|<&^ | LOCK|xgS@qM# |
Roche Earnings: Continuing Steady Underlying Growth in 2026 as Late-Stage Pipeline Shines
Roche saw 7% sales growth at constant exchange rates in 2025 (2% as reported), with core earnings per share growth of 11% (4% as reported). Management guided to mid-single-digit sales growth and high-single-digit core EPS growth in 2026 at constant currencies. The ADRs rose 5% intraday on Jan. 29.
